Want to see GB:EDEN full AI Analyst Report?
Top Page
Eden Research
(LSE:EDEN)
Select Model
Select Model
Rating:48Neutral
Price Target:
2.00 p
▼(-9.09% Downside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by ongoing losses and recurring cash burn, despite a conservatively financed balance sheet. Technicals are also weak with the stock in a clear downtrend and negative momentum (though oversold). Valuation is constrained by the company’s loss-making profile and the lack of a dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage and substantial equity provide financial resilience while Eden remains loss-making. This reduces near-term balance-sheet pressure and preserves flexibility to fund product development, registrations and commercial expansion.
Negative Factors
Persistent operating losses
Eden has not yet demonstrated recurring operating profitability despite positive gross profit. Continued losses indicate that overhead, research and regulatory spending remain too high relative to revenue, limiting self-funded growth and increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and substantial equity provide financial resilience while Eden remains loss-making. This reduces near-term balance-sheet pressure and preserves flexibility to fund product development, registrations and commercial expansion.
Read all positive factors
Eden Research (EDEN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£17.67M
Dividend YieldN/A
Average Volume (3M)841.38K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees23
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding803,363,000
10 Day Avg. Volume339,502
30 Day Avg. Volume841,385
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.23
Price to Sales (P/S)3.92
P/FCF Ratio-6.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.10M
Eden Research Business Overview & Revenue Model
Company Description
Established in 1995 and headquartered in Abingdon, UK, Eden Research plc specializes in delivering sustainable products for crop protection, animal well-being, and consumer markets throughout the United Kingdom and wider European region. Its agric...
How the Company Makes Money
Eden Research primarily makes money by commercialising its bio-based crop protection products and technology through licensing and distribution arrangements with partners. Revenue is generated mainly from (1) product sales and related partner purc...
Eden Research Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.62M | 3.88M | 4.30M | 3.19M | 1.83M | 1.23M |
| Gross Profit | 1.39M | 1.04M | 1.87M | 1.77M | 207.14K | 28.32K |
| EBITDA | -1.93M | -1.56M | -1.59M | -6.24M | -1.83M | -2.72M |
| Net Income | -2.35M | -1.96M | -1.91M | -6.49M | -2.24M | -2.79M |
Balance Sheet | ||||||
| Total Assets | 13.46M | 16.34M | 15.41M | 16.59M | 12.91M | 15.03M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 1.52M | 3.67M | 7.41M | 1.99M | 3.83M |
| Total Debt | 571.86K | 671.91K | 168.73K | 229.77K | 355.32K | 398.35K |
| Total Liabilities | 2.85M | 3.91M | 3.57M | 3.05M | 2.17M | 2.20M |
| Stockholders Equity | 10.58M | 12.42M | 11.82M | 13.52M | 10.72M | 12.80M |
Cash Flow | ||||||
| Free Cash Flow | -710.00K | -2.45M | -3.60M | -1.80M | -1.74M | -3.34M |
| Operating Cash Flow | -209.90K | -2.44M | -1.01M | -1.70M | -683.10K | -1.62M |
| Investing Cash Flow | -2.72M | -2.41M | -2.48M | -1.72M | -1.05M | -1.73M |
| Financing Cash Flow | -150.87K | 2.64M | -155.53K | 8.90M | -150.35K | -90.39K |
Eden Research Technical Analysis
Negative
2.20
Price Trends
2.57
Negative
2.96
Negative
3.09
Negative
Market Momentum
-0.11
Negative
29.59
Positive
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EDEN, the sentiment is Negative. The current price of 2.2 is below the 20-day moving average (MA) of 2.26, below the 50-day MA of 2.57, and below the 200-day MA of 3.09, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 29.59 is Positive, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EDEN.
Eden Research Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | £4.55B | 58.82 | 3.65% | 3.34% | 3.36% | -43.08% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | £1.00B | 18.47 | 11.29% | 1.89% | -11.73% | ― | |
53 Neutral | £177.06M | -1.46 | -13.27% | 9.77% | -4.98% | -43.98% | |
52 Neutral | £27.92M | -27.46 | -15.66% | ― | 57.55% | 2.94% | |
48 Neutral | £17.67M | -6.11 | -16.16% | ― | ― | ― |
* Basic Materials Sector Average
GB:EDEN
Eden Research
2.20
-0.90
-29.03%
GB:CRDA
Croda International
3,327.00
885.41
36.26%
GB:ELM
Elementis
176.60
14.45
8.91%
GB:ITX
Itaconix
208.00
75.50
56.98%
GB:SYNT
Synthomer
107.00
47.70
80.44%
Eden Research Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Eden Research boosts revenue and global approvals as losses widen
Positive
Aug 26, 2026
Eden Research reported preliminary results for the 15 months to 31 March 2026, with revenue rising to £4.9 million but operating losses widening to £2.9 million and cash falling to £1.5 million. The company completed a £10.8 mi...
Business Operations and StrategyFinancial Disclosures
Eden Research sets date for 2026 preliminary results and investor briefing
Positive
Aug 25, 2026
Eden Research plc, a UK-listed leader in sustainable biopesticides and biocontrol technologies, develops plant-derived crop protection products and a biodegradable microencapsulation platform for global agriculture and related markets. Its key off...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Eden Research Wins Mevalone Approvals in Slovakia and Egypt, Opening North African Market
Positive
Aug 4, 2026
Eden Research has secured regulatory approvals for its Botrytis fungicide Mevalone in Slovakia and, under the Trilogy brand, in Egypt, extending its reach in both Central Europe and North Africa. In Slovakia, the product will be marketed by Biocon...
Business Operations and Strategy
Eden Research Retains London Stock Exchange Green Economy Mark for 2026
Positive
Jun 25, 2026
Eden Research, a UK-listed biopesticide and biocontrol specialist, develops plant-derived crop protection products and biodegradable microencapsulation technologies for agriculture and related industries. Its marketed products Mevalone and Cedroz ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.